15 results on '"Heart Conduction System/drug effects"'
Search Results
2. Changes in QTc associated with a rapid bolus dose of dexmedetomidine in patients receiving TIVA: a retrospective study.
- Author
-
Görges, Matthias, Whyte, Simon D., Sanatani, Shubhayan, Dawes, Joy, Montgomery, Carolyne J., and Ansermino, J. Mark
- Subjects
- *
PEDIATRIC anesthesia , *INTRAVENOUS anesthesia , *ELECTROCARDIOGRAPHY , *BOLUS drug administration , *BRADYCARDIA , *HEART beat measurement - Abstract
Background Clinical indications for the perioperative use of dexmedetomidine in pediatric anesthesia are accumulating. However, in 2013, dexmedetomidine was added to the list of medications with possible risk of prolonging the QT interval and/or inducing Torsades de Pointes. Unfortunately, current evidence for dexmedetomidine-induced QT prolongation is sparse and somewhat contradictory. Objective The purpose of this study was to evaluate temporal changes in corrected QT interval ( QTc) after a rapid bolus administration of dexmedetomidine under total intravenous anesthesia ( TIVA) with a standardized propofol and remifentanil administration. Methods Electrocardiography ( ECG) and corresponding trend data were extracted from automated electronic data capture of physiological monitoring. Ten-second epochs of ECG data were extracted in 1-min intervals for 12 min, starting 1 min before dexmedetomidine bolus administration, and ending 10 min after. QT intervals were extracted using an automated routine in MATLAB, and corrected for heart rate (HR) using Bazett's ( QTcB) and Fridericia's formulas ( QTcF). QTcB and QTcF were compared using Wilcoxon signed-rank test between baseline measurements and the subsequent four interval values. Results Data from 21 subjects (17 male) with median (range) age 7.1 (5.4-9.5) yr, weight 23.6 (16.2-36.7) kg, and height 121 (103-140) cm were analyzed. Bolus administration of dexmedetomidine reduced HR in all subjects (median 22%), and caused transient reduction of QT interval, with its peak at 1-min postbolus administration: QTcB (median reduction 30.7 ms, P < 0.001) or QTcF (median reduction 15.4 ms, P = 0.001); QT shortening became statistically insignificant 4 min following dexmedetomidine bolus administration for QTcB and 2 min for QTcF. Conclusion In this study, a rapid bolus of dexmedetomidine transiently shortened corrected QT intervals. However, these effects are confounded by dexmedetomidine-induced bradycardia. These findings should be confirmed in pediatric studies without concomitant TIVA administration and with optimized correction of baseline HR. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
3. Electrophysiologic effects of the IK1 inhibitor PA-6 are modulated by extracellular potassium in isolated guinea pig hearts
- Author
-
Hoeker, Gregory S, Skarsfeldt, Mark A, Jespersen, Thomas, Poelzing, Steven, Hoeker, Gregory S, Skarsfeldt, Mark A, Jespersen, Thomas, and Poelzing, Steven
- Abstract
The pentamidine analog PA-6 was developed as a specific inward rectifier potassium current (IK1) antagonist, because established inhibitors either lack specificity or have side effects that prohibit their use in vivo. We previously demonstrated that BaCl2, an established IK1inhibitor, could prolong action potential duration (APD) and increase cardiac conduction velocity (CV). However, few studies have addressed whether targeted IK1inhibition similarly affects ventricular electrophysiology. The aim of this study was to determine the effects of PA-6 on cardiac repolarization and conduction in Langendorff-perfused guinea pig hearts. PA-6 (200 nm) or vehicle was perfused into ex-vivo guinea pig hearts for 60 min. Hearts were optically mapped with di-4-ANEPPS to quantify CV and APD at 90% repolarization (APD90). Ventricular APD90was significantly prolonged in hearts treated with PA-6 (115 ± 2% of baseline; P < 0.05), but not vehicle (105 ± 2% of baseline). PA-6 slightly, but significantly, increased transverse CV by 7%. PA-6 significantly prolonged APD90during hypokalemia (2 mmol/L [K+]o), although to a lesser degree than observed at 4.56 mmol/L [K+]oIn contrast, the effect of PA-6 on CV was more pronounced during hypokalemia, where transverse CV with PA-6 (24 ± 2 cm/sec) was significantly faster than with vehicle (13 ± 3 cm/sec, P < 0.05). These results show that under normokalemic conditions, PA-6 significantly prolonged APD90, whereas its effect on CV was modest. During hypokalemia, PA-6 prolonged APD90to a lesser degree, but profoundly increased CV Thus, in intact guinea pig hearts, the electrophysiologic effects of the IK1inhibitor, PA-6, are [K+]o-dependent.
- Published
- 2017
4. Hypertension and cardiac arrhythmias: A consensus document fromthe European Heart RhythmAssociation (EHRA) and ESC Council on Hypertension, endorsed by the Heart RhythmSociety (HRS), Asia-Pacific Heart RhythmSociety (APHRS) and Sociedad Latinoamericana de Estimulacion Cardiaca y Electrofisiologia (SOLEACE)
- Author
-
Lip, Gregory Y. H., Coca, Antonio, Kahan, Thomas, Boriani, Giuseppe, Manolis, Antonis S., Olsen, Michael Hecht, Oto, Ali, Potpara, Tatjana S., Steffel, Jan, Marin, Francisco, de Oliveira Figueiredo, Marcio Jansen, de Simone, Giovanni, Tzou, Wendy S., Chiang, Chern-En, Williams, Bryan, Dan, Gheorghe-Andrei, Gorenek, Bulent, Fauchier, Laurent, Savelieva, Irina, Hatala, Robert, van Gelder, Isabelle, Brguljan-Hitij, Jana, Erdine, Serap, Lovic, Dragan, Kim, Young-Hoon, Salinas-Arce, Jorge, Field, Michael, Cardiovascular Centre (CVC), Lip, Gregory Y. H., Coca, Antonio, Kahan, Thoma, Boriani, Giuseppe, Manolis, Antonis S., Olsen, Michael Hecht, Oto, Ali, Potpara, Tatjana S., Steffel, Jan, Marín, Francisco, De Oliveira Figueiredo, Márcio Jansen, De Simone, Giovanni, Tzou, Wendy S., Chiang, Chern-En, Williams, Bryan, Dan, Gheorghe-Andrei, Gorenek, Bulent, Fauchier, Laurent, Savelieva, Irina, Hatala, Robert, Van Gelder, Isabelle, Brguljan-Hitij, Jana, Erdine, Serap, Lovic, Dragan, Kim, Young-Hoon, Salinas-Arce, Jorge, and Field, Michael
- Subjects
Cost-Benefit Analysis ,Blood Pressure ,END-POINT REDUCTION ,030204 cardiovascular system & hematology ,Arrhythmias ,Left ventricular hypertrophy ,Heart Conduction System/drug effects ,Coronary artery disease ,0302 clinical medicine ,Risk Factors ,030212 general & internal medicine ,INCIDENT ATRIAL-FIBRILLATION ,Stroke ,HIGH BLOOD-PRESSURE ,Arrhythmias, Cardiac/diagnosis ,CLINICAL CLASSIFICATION SCHEMES ,Atrial fibrillation ,Health Care Costs ,Hypertensive heart disease ,Death ,Treatment Outcome ,PRESERVED EJECTION FRACTION ,Hypertension/diagnosis ,Hypertension ,Cardiology ,cardiovascular system ,CORONARY-ARTERY-DISEASE ,Cardiology and Cardiovascular Medicine ,Cardiac ,Arrhythmia ,medicine.medical_specialty ,Consensus ,Risk Assessment ,Blood Pressure/drug effects ,03 medical and health sciences ,ADDITIONAL RISK-FACTOR ,EHRA consensus document ,Heart Conduction System ,LEFT-VENTRICULAR HYPERTROPHY ,Internal medicine ,Physiology (medical) ,medicine ,Humans ,cardiovascular diseases ,Death, Sudden, Cardiac/epidemiology ,Antihypertensive Agents ,business.industry ,STROKE PREVENTION ,Antihypertensive Agents/adverse effects ,Cardiac arrhythmia ,Arrhythmias, Cardiac ,medicine.disease ,PILOT GENERAL REGISTRY ,Sudden ,Blood pressure ,Death, Sudden, Cardiac ,Heart failure ,business - Abstract
Hypertension is a common cardiovascular risk factor leading to heart failure (HF), coronary artery disease, stroke, peripheral artery disease and chronic renal insufficiency. Hypertensive heart disease can manifest as many cardiac arrhythmias, most commonly being atrial fibrillation (AF). Both supraventricular and ventricular arrhythmias may occur in hypertensive patients, especially in those with left ventricular hypertrophy (LVH) or HF. Also, some of the antihypertensive drugs commonly used to reduce blood pressure, such as thiazide diuretics, may result in electrolyte abnormalities (e.g. hypokalaemia, hypomagnesemia), further contributing to arrhythmias, whereas effective control of blood pressure may prevent the development of the arrhythmias such as AF. In recognizing this close relationship between hypertension and arrhythmias, the European Heart Rhythm Association (EHRA) and the European Society of Cardiology (ESC) Council on Hypertension convened a Task Force, with representation from the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS), and Sociedad Latinoamericana de Estimulacion Cardiaca y Electrofisiologia (SOLEACE), with the remit to comprehensively review the available evidence to publish a joint consensus document on hypertension and cardiac arrhythmias, and to provide up-to-date consensus recommendations for use in clinical practice. The ultimate judgment regarding care of a particular patient must be made by the healthcare provider and the patient in light of all of the circumstances presented by that patient.
- Published
- 2017
5. A key role of TRPC channels in the regulation of electromechanical activity of the developing heart
- Author
-
Eric Raddatz, Elodie Robin, and Jessica Sabourin
- Subjects
medicine.medical_specialty ,Time Factors ,Calcium Channels, L-Type ,Nifedipine ,Physiology ,Blotting, Western ,Chick Embryo ,030204 cardiovascular system & hematology ,Polymerase Chain Reaction ,TRPC1 ,Electrocardiography ,03 medical and health sciences ,Transient receptor potential channel ,0302 clinical medicine ,TRPC3 ,Heart Conduction System ,Heart Rate ,Physiology (medical) ,Internal medicine ,medicine ,Animals ,Ventricular Function ,RNA, Messenger ,Atrioventricular Block ,TRPC ,TRPC Cation Channels ,Aminoquinolines/pharmacology ,Aminoquinolines/toxicity ,Atrioventricular Block/chemically induced ,Atrioventricular Block/metabolism ,Calcium Channel Blockers/pharmacology ,Calcium Channels, L-Type/drug effects ,Calcium Channels, L-Type/metabolism ,Dose-Response Relationship, Drug ,Electrophysiologic Techniques, Cardiac ,Gene Expression Regulation, Developmental ,Heart/drug effects ,Heart/embryology ,Heart Conduction System/drug effects ,Heart Conduction System/embryology ,Myocardial Contraction ,Nifedipine/pharmacology ,Pyrazoles/pharmacology ,Pyrazoles/toxicity ,RNA, Messenger/metabolism ,TRPC Cation Channels/antagonists & inhibitors ,TRPC Cation Channels/genetics ,030304 developmental biology ,0303 health sciences ,Voltage-dependent calcium channel ,Chemistry ,Calcium channel ,Heart ,Calcium Channel Blockers ,3. Good health ,Endocrinology ,Aminoquinolines ,cardiovascular system ,Pyrazoles ,Electrical conduction system of the heart ,Cardiology and Cardiovascular Medicine - Abstract
Aims It is well established that dysfunction of voltage-dependent ion channels results in arrhythmias and conduction disturbances in the foetal and adult heart. However, the involvement of voltage-insensitive cationic TRPC (transient receptor potential canonical) channels remains unclear. We assessed the hypothesis that TRPC channels play a crucial role in the spontaneous activity of the developing heart.Methods and results TRPC isoforms were investigated in isolated hearts obtained from 4-day-old chick embryos. Using RT-PCR, western blotting and co-immunoprecipitation, we report for the first time that TRPC1, 3, 4, 5, 6, and 7 isoforms are expressed at the mRNA and protein levels and that they can form a macromolecular complex with the alpha 1C subunit of the L-type voltage-gated calcium channel (Cav1.2) in atria and ventricle. Using ex vivo electrocardiograms, electrograms of isolated atria and ventricle and ventricular mechanograms, we found that inhibition of TRPC channels by SKF-96365 leads to negative chrono-, dromo-, and inotropic effects, prolongs the QT interval, and provokes first-and second-degree atrioventricular blocks. Pyr3, a specific antagonist of TRPC3, affected essentially atrioventricular conduction. On the other hand, specific blockade of the L-type calcium channel with nifedipine rapidly stopped ventricular contractile activity without affecting rhythmic electrical activity.Conclusions These results give new insights into the key role that TRPC channels, via interaction with the Cav1.2 channel, play in regulation of cardiac pacemaking, conduction, ventricular activity, and contractility during cardiogenesis.
- Published
- 2011
6. The effect of insulin on cardiac autonomic balance predicts weight reduction after gastric bypass
- Author
-
Gilles Chassot, Alain Golay, Philippe Morel, Olivier Huber, Françoise Assimacopoulos-Jeannet, Elisabetta Bobbioni-Harsch, Juan Sztajzel, Katia Sievert, T Lehmann, and V. Barthassat
- Subjects
Blood Glucose ,Adult ,medicine.medical_specialty ,Endocrinology, Diabetes and Metabolism ,medicine.medical_treatment ,Gastric Bypass ,Obesity, Morbid/surgery ,Heart Conduction System/drug effects ,Body Mass Index ,Heart Conduction System ,Weight loss ,Hyperinsulinism ,Internal medicine ,Diabetes mellitus ,Weight Loss ,Internal Medicine ,medicine ,Insulin ,Humans ,Pancreatic hormone ,ddc:613 ,ddc:616 ,ddc:617 ,Blood Glucose/metabolism ,business.industry ,Stomach ,Gastric Bypass/methods ,Anastomosis, Roux-en-Y ,Anastomosis, Roux-en-Y/methods ,medicine.disease ,Obesity, Morbid ,Autonomic nervous system ,Insulin/blood/pharmacology ,medicine.anatomical_structure ,Endocrinology ,Cardiology ,Regression Analysis ,Female ,medicine.symptom ,business ,Body mass index - Abstract
Aims/hypothesis: The aim of this study was to assess the predictive role of autonomic reactivity in body weight loss induced by gastric bypass. Methods: A group of 22 morbidly obese subjects, who were due to undergo a gastric bypass, were submitted, before surgery, to a euglycaemic-hyperinsulinaemic clamp, during which a continuous recording of the ECG was performed. The effect of insulin on cardiac autonomic balance was evaluated by performing power spectral analysis of heart rate variability. The low-to-high frequency ratio was calculated before and during the clamp and its modifications were expressed as % delta low-to-high frequency ratio (%Δ L: H). Results: Preoperative %Δ L: H showed a significant (p=0.0009, r 2=0.43), positive relationship to the reduction of body weight, measured 1 year after surgery and expressed as % excess weight loss (% EWL). Preoperative BMI was also significantly (p=0.0009, r 2=0.43) negatively related to the 12-month % EWL. In a multiple regression analysis, %Δ L: H remained a significant (p=0.003), independent predictor of body weight loss, even when preoperative BMI or age, % fat mass, insulinaemia and glucose disposal were taken into account. Conclusions/interpretation: The best correction of excess body weight was achieved by those obese subjects who had a preserved capacity to shift their cardiac autonomic balance towards a sympathetic prevalence in response to an euglycaemic-hyperinsulinaemic clamp. Further studies are needed to elucidate the mechanisms through which the autonomic nervous system influences weight reduction
- Published
- 2005
7. Electrophysiologic effects of the I K 1 inhibitor PA-6 are modulated by extracellular potassium in isolated guinea pig hearts
- Author
-
Steven Poelzing, Thomas Jespersen, Mark Alexander Skarsfeldt, Gregory S. Hoeker, Biomedical Engineering and Mechanics, and Fralin Biomedical Research Institute
- Subjects
Male ,0301 basic medicine ,Potassium Channels ,Hypokalemia/physiopathology ,Physiology ,Barium Compounds ,Action Potentials ,Anthraquinones ,Pyridinium Compounds ,Voltage-Sensitive Dye Imaging/methods ,030204 cardiovascular system & hematology ,inward rectifier current ,Action Potentials/drug effects ,Heart Conduction System/drug effects ,Nerve conduction velocity ,0302 clinical medicine ,Pyridinium Compounds/analysis ,Membrane Physiology ,Medicine ,Potassium Channels/drug effects ,Original Research ,Inward-rectifier potassium ion channel ,potassium ,Anthraquinones/administration & dosage ,Heart ,Hypokalemia ,Heart/physiology ,3. Good health ,Heart Ventricles/drug effects ,cardiovascular system ,medicine.symptom ,medicine.medical_specialty ,Chlorides/administration & dosage ,Heart Ventricles ,Guinea Pigs ,Potassium/metabolism ,Potassium Channel Blockers/administration & dosage ,Guinea pig ,conduction velocity ,03 medical and health sciences ,Chlorides ,Pentamidine/analogs & derivatives ,pentamidine ,Heart Conduction System ,Physiology (medical) ,Internal medicine ,Cardiac conduction ,Potassium Channel Blockers ,Animals ,Repolarization ,repolarization ,business.industry ,Antagonist ,Barium Compounds/administration & dosage ,Action potential ,Voltage-Sensitive Dye Imaging ,Electrophysiological Phenomena ,Electrophysiology ,030104 developmental biology ,Endocrinology ,business - Abstract
The pentamidine analog PA-6 was developed as a specific inward rectifier potassium current (I-K1) antagonist, because established inhibitors either lack specificity or have side effects that prohibit their use in vivo. We previously demonstrated that BaCl2, an established I-K1 inhibitor, could prolong action potential duration (APD) and increase cardiac conduction velocity (CV). However, few studies have addressed whether targeted I-K1 inhibition similarly affects ventricular electrophysiology. The aim of this study was to determine the effects of PA-6 on cardiac repolarization and conduction in Langendorff-perfused guinea pig hearts. PA-6 (200 nm) or vehicle was perfused into ex-vivo guinea pig hearts for 60 min. Hearts were optically mapped with di-4-ANEPPS to quantify CV and APD at 90% repolarization (APD(90)). Ventricular APD90 was significantly prolonged in hearts treated with PA-6 (115 +/- 2% of baseline; P < 0.05), but not vehicle (105 +/- 2% of baseline). PA-6 slightly, but significantly, increased transverse CV by 7%. PA-6 significantly prolonged APD90 during hypokalemia (2 mmol/L [K+](o)), although to a lesser degree than observed at 4.56 mmol/L [K+](o). In contrast, the effect of PA-6 on CV was more pronounced during hypokalemia, where transverse CV with PA-6 (24 +/- 2 cm/sec) was significantly faster than with vehicle (13 +/- 3 cm/sec, P < 0.05). These results show that under normokalemic conditions, PA-6 significantly prolonged APD90, whereas its effect on CV was modest. During hypokalemia, PA-6 prolonged APD90 to a lesser degree, but profoundly increased CV. Thus, in intact guinea pig hearts, the electrophysiologic effects of the I-K1 inhibitor, PA-6, are [K+](o)-dependent. Novo Nordisk Foundation; National Institutes of Health [R01-HL102298] This work was supported in part by the Novo Nordisk Foundation (TJ) and the National Institutes of Health R01 (SP, R01-HL102298).
- Published
- 2017
8. Specific inhibition of HCN channels slows rhythm differently in atria, ventricle and outflow tract and stabilizes conduction in the anoxic-reoxygenated embryonic heart model
- Author
-
Sarah Pedretti, Alexandre Sarre, Stephany Gardier, and Eric Raddatz
- Subjects
medicine.medical_specialty ,Potassium Channels ,Time Factors ,Heart Ventricles ,Blotting, Western ,Cyclic Nucleotide-Gated Cation Channels ,Chick Embryo ,Biology ,Animals ,Anoxia/drug therapy ,Anoxia/embryology ,Anti-Arrhythmia Agents/pharmacology ,Arrhythmias, Cardiac/embryology ,Arrhythmias, Cardiac/metabolism ,Benzazepines/pharmacology ,Biological Clocks/drug effects ,Cyclic Nucleotide-Gated Cation Channels/antagonists & inhibitors ,Cyclic Nucleotide-Gated Cation Channels/metabolism ,Disease Models, Animal ,Dose-Response Relationship, Drug ,Electrocardiography ,Excitation Contraction Coupling/drug effects ,Heart/drug effects ,Heart/embryology ,Heart Atria/drug effects ,Heart Atria/metabolism ,Heart Conduction System/drug effects ,Heart Conduction System/embryology ,Heart Rate/drug effects ,Heart Ventricles/drug effects ,Heart Ventricles/metabolism ,Myocardial Contraction/drug effects ,Oxygen/metabolism ,Potassium Channels/metabolism ,Tissue Culture Techniques ,Contractility ,Biological Clocks ,Heart Conduction System ,Heart Rate ,Internal medicine ,Hyperpolarization-Activated Cyclic Nucleotide-Gated Channels ,medicine ,Ivabradine ,Heart Atria ,PR interval ,Hypoxia ,Excitation Contraction Coupling ,Pharmacology ,Embryonic heart ,Heart development ,Arrhythmias, Cardiac ,Heart ,Benzazepines ,Myocardial Contraction ,Potassium channel ,Oxygen ,medicine.anatomical_structure ,Ventricle ,Cardiology ,cardiovascular system ,Electrical conduction system of the heart ,Anti-Arrhythmia Agents ,medicine.drug - Abstract
The hyperpolarization-activated cyclic nucleotide-gated (HCN) channels are expressed in pacemaker cells very early during cardiogenesis. This work aimed at determining to what extent these channels are implicated in the electromechanical disturbances induced by a transient oxygen lack which may occur in utero. Spontaneously beating hearts or isolated ventricles and outflow tracts dissected from 4-day-old chick embryos were exposed to a selective inhibitor of HCN channels (ivabradine 0.1-10microM) to establish a dose-response relationship. The effects of ivabradine on electrocardiogram, excitation-contraction coupling and contractility of hearts submitted to anoxia (30min) and reoxygenation (60min) were also determined. The distribution of the predominant channel isoform, HCN4, was established in atria, ventricle and outflow tract by immunoblotting. Intrinsic beating rate of atria, ventricle and outflow tract was 164+/-22 (n=10), 78+/-24 (n=8) and 40+/-12bpm (n=23, mean+/-SD), respectively. In the whole heart, ivabradine (0.3microM) slowed the firing rate of atria by 16% and stabilized PR interval. These effects persisted throughout anoxia-reoxygenation, whereas the variations of QT duration, excitation-contraction coupling and contractility, as well as the types and duration of arrhythmias were not altered. Ivabradine (10microM) reduced the intrinsic rate of atria and isolated ventricle by 27% and 52%, respectively, whereas it abolished activity of the isolated outflow tract. Protein expression of HCN4 channels was higher in atria and ventricle than in the outflow tract. Thus, HCN channels are specifically distributed and control finely atrial, ventricular and outflow tract pacemakers as well as conduction in the embryonic heart under normoxia and throughout anoxia-reoxygenation.
- Published
- 2010
9. Sympathoexcitation increases the QT/RR slope in healthy men: differential effects of hypoxia, dobutamine, and phenylephrine
- Author
-
F.E.S.C. Philippe Van De Borne M.D., Atul Pathak, Marko Gujic, Olivier Xhaet, Boutaïna Najem, Jean-Paul Degaute, Anne Houssiere, Jean-Francois Argacha, Department of Cardiology, Hôpital Erasme [Bruxelles] (ULB), Faculté de Médecine [Bruxelles] (ULB), Université libre de Bruxelles (ULB)-Université libre de Bruxelles (ULB)-Faculté de Médecine [Bruxelles] (ULB), Université libre de Bruxelles (ULB)-Université libre de Bruxelles (ULB), Unité de recherche sur les obésités, IFR 31 Louis Bugnard (IFR 31), Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM), Simon, Marie Francoise, Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Toulouse [Toulouse]-Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Toulouse [Toulouse]-Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM), Clinical sciences, Cardio-vascular diseases, and Cardiology
- Subjects
Adult ,Male ,medicine.medical_specialty ,Cardiac output ,MESH: Phenylephrine ,MESH: Anoxia ,Phenylephrine/pharmacology ,Stimulation ,030204 cardiovascular system & hematology ,Heart Conduction System/drug effects ,MESH: Heart Conduction System ,Phenylephrine ,03 medical and health sciences ,0302 clinical medicine ,MESH: Dobutamine ,Heart Conduction System ,Dobutamine ,Physiology (medical) ,Internal medicine ,medicine ,Humans ,Hypoxia ,Hypoxia/physiopathology ,MESH: Humans ,business.industry ,Sympatholytics/pharmacology ,Healthy subjects ,MESH: Sympatholytics ,MESH: Adult ,Hypoxia (medical) ,Differential effects ,MESH: Male ,Dobutamine/pharmacology ,Anesthesia ,Sympatholytics ,Reflex ,Cardiology ,medicine.symptom ,Cardiology and Cardiovascular Medicine ,business ,030217 neurology & neurosurgery ,medicine.drug - Abstract
International audience; INTRODUCTION: Dynamic ventricular repolarization assessed by QT/RR slopes studies the effects of modifications in cardiac repolarization independently of variations in RR interval (RR). The effects of changes in sympathetic and vagal activity on the QT/RR slope are controversial. We tested the hypothesis that sympathoexcitation is an important determinant of the QT/RR slope. METHODS AND RESULTS: We compared the effects of a reflex sympathetic activation in response to hypoxia, to the direct effects of the infusion of the beta-adrenergic agent dobutamine, on the QTa (apex) and QTe (end)/RR slopes. Dobutamine was titrated to obtain similar increases in cardiac output than with hypoxia. Cardiac vagal activity was estimated by rMSSD and pNN50. In a second group of healthy subjects, we assessed the effect of a reflex cardiac vagal activation in response to phenylephrine infusion on the same variables. We observed a similar increase in QTa and QTe slopes during hypoxia and dobutamine (both P < 0.017 vs. normoxia), despite divergent changes in cardiac vagal activity, as rMSSD and pNN50 decreased with hypoxia compared to normoxia (P < 0.001) but increased during dobutamine infusion compared to hypoxia (P < 0.017). In contrast, these slopes did not change during the rises in rMSSD and pNN50 elicited by phenylephrine (P > 0.7). CONCLUSION: Beta-adrenergic stimulation induces comparable increases in the QT/RR slopes than hypoxia, but in the presence of a larger cardiac vagal activity. Vagal cardiac activation by phenylephrine does not change the QT slopes. This reveals that the sympathetic system is an important determinant of QT/RR dynamicity in healthy men.
- Published
- 2008
10. Transient, High-Grade Atrioventricular Block from High-Dose Cyclophosphamide.
- Author
-
Agarwal, Nayan and Burkart, Thomas A.
- Subjects
- *
STEM cell transplantation , *ATRIOVENTRICULAR node - Abstract
Cyclophosphamide, an alkylation agent, is widely used in stem cell transplantation for its antineoplastic and myeloablative properties. Congestive heart failure, pericarditis, and arrhythmias are well-known cardiac sequelae of high-dose cyclophosphamide therapy; however, high-grade atrioventricular block has rarely been reported. We present the case of a 71-year-old man who developed a high degree of atrioventricular block several hours after therapy with high-dose cyclophosphamide. After treatment with a temporary pacemaker and cessation of cyclophosphamide, the patient experienced no more events. Before administering cyclophosphamide, evaluating patients for underlying conduction abnormalities is advisable. Agents other than cyclophosphamide are available. [ABSTRACT FROM AUTHOR]
- Published
- 2013
11. Intrapericardial drug delivery: pharmacologic properties and long-term safety in swine
- Author
-
Christos S. Katsouras, Marios Marselos, Nikolaos Kazakos, Lampros K. Michalis, Theofilos M. Kolettis, Panagiotis Stefanou, Constantinos Seferiadis, Lamprini Pappa, Dimitrios Sideris, Vassilios Koulouras, Vassiliki D. Malamou–Mitsi, and Dimitra Niokou
- Subjects
Anti-Arrhythmia Agents/*administration & dosage ,Male ,Digoxin ,Swine ,Digitalis ,Procainamide ,QT interval ,Digitalis Glycosides/*administration & dosage ,Heart Conduction System/drug effects ,QRS complex ,Catheters, Indwelling ,Fibrosis ,Heart Conduction System ,medicine ,Pericardium ,Animals ,biology ,Procainamide/*administration & dosage ,business.industry ,Digitalis Glycosides ,medicine.disease ,biology.organism_classification ,Catheter ,medicine.anatomical_structure ,Anesthesia ,Cardiology and Cardiovascular Medicine ,business ,Anti-Arrhythmia Agents ,medicine.drug - Abstract
Background: Intrapericardial drug delivery is a promising new technique, but the pharmacologic properties of various agents delivered via this route are not known. Furthermore, the long-term safety of intrapericardial catheters has not been previously examined. Methods: Using a pericardial access device, a catheter connected to a drug-delivery system was implanted in five pigs. Plasma levels and electrocardiographic measurements were obtained after intravenous and intrapericardial administration of digoxin and procainamide. Histological examination was performed after the device had been implanted for a total of 6 months. Results: The QTc interval did not change significantly after digoxin or procainamide intravenous administration. QTc decreased by 47±23 ms ( p =0.046) 8 h after digoxin intrapericardial administration and increased by 128±60 ms ( p =0.002) 1 h after procainamide intrapericardial administration. The QRS duration did not change significantly after intravenous administration of either agent, but it increased by 17±9 ms ( p =0.004) 1 h and by 15±4 ms ( p =0.01) 8 h after procainamide intrapericardial administration. After intravenous procainamide the RR interval decreased, but it did not change significantly after intrapericardial administration of either agent. Histology showed moderate inflammatory infiltration and fibrosis adjacent to the catheter. Conclusions: Intrapericardial delivery of digitalis and procainamide produces unique electrophysiological properties. In contrast to satisfactory success of the implantation technique, long-term dwell of the catheter in the pericardium induces moderate, albeit probably clinically significant, fibrosis.
- Published
- 2005
12. A pharmacokinetic-pharmacodynamic model for the quantitative prediction of dofetilide clinical QT prolongation from human ether-a-go-go-related gene current inhibition data.
- Author
-
Jonker, DM, Kenna, Leslie A, Leishman, Derek, Wallis, Rob, Milligan, Peter A, Jonsson, E Niclas, Jonker, DM, Kenna, Leslie A, Leishman, Derek, Wallis, Rob, Milligan, Peter A, and Jonsson, E Niclas
- Published
- 2005
13. In-hospital prescription of QT-prolonging drugs in a cohort of more than 100,000 patients
- Author
-
Baptista, Rui, Silva, Sebastião, Dias, Patrícia, Monteiro, Pedro, Feio, José, and Providência, Luís A.
- Published
- 2011
- Full Text
- View/download PDF
14. Adenosine administration during hybrid atrial fibrillation ablation to test dormant pulmonary vein conduction
- Author
-
Harry J.G.M. Crijns, Mark La Meir, Mindy Vroomen, Laurent Pison, Jos G. Maessen, Cardio-vascular diseases, Surgical clinical sciences, Promovendi CD, Cardiologie, RS: CARIM - R2.01 - Clinical atrial fibrillation, MUMC+: MA Cardiothoracale Chirurgie (3), RS: CARIM - R2.12 - Surgical intervention, CTC, MUMC+: MA Cardiologie (9), and MUMC+: MA Med Staf Spec Cardiologie (9)
- Subjects
Male ,Adenosine ,medicine.medical_treatment ,Treatment outcome ,MULTICENTER ,030204 cardiovascular system & hematology ,Ablation ,Heart Conduction System/drug effects ,Pulmonary vein ,Electrocardiography ,0302 clinical medicine ,Dormant conduction ,Medicine ,030212 general & internal medicine ,CATHETER ABLATION ,SITES ,Atrial fibrillation ,Middle Aged ,Catheter Ablation/methods ,Treatment Outcome ,Adenosine/administration & dosage ,Pulmonary Veins ,Anesthesia ,cardiovascular system ,Cardiology ,Female ,TRIAL ,Af ablation ,Cardiology and Cardiovascular Medicine ,medicine.drug ,Adult ,medicine.medical_specialty ,Pulmonary Veins/drug effects ,BIPOLAR ,Catheter ablation ,Pulmonary vein isolation ,Article ,03 medical and health sciences ,Heart Conduction System ,Internal medicine ,Monitoring, Intraoperative ,Physiology (medical) ,Atrial Fibrillation/diagnosis ,Humans ,Monitoring, Intraoperative/methods ,Aged ,business.industry ,fungi ,Electrocardiography/drug effects ,medicine.disease ,Hybrid ,business ,FOLLOW-UP - Abstract
Background Adenosine administration after initial pulmonary vein isolation (PVI) reveals dormant conduction and predicts atrial fibrillation (AF) recurrence. Elimination of dormant conduction when present may increase a long-term success rate of AF ablation procedures. There are no studies till date using adenosine to reveal acute reconduction of pulmonary veins (PVs) after epicardial PVI during a hybrid AF ablation procedure.Methods We included 24 patients (21 male, 55 +/- 9 years) undergoing hybrid ablation for symptomatic paroxysmal (n = 12) and persistent (n = 12) AF, using an epicardial bipolar radiofrequency clamp to perform PVI. All antiarrhythmic medications were discontinued 5 days prior to the procedure, except for patients on amiodarone. Thirty minutes after PVI and once sinus rhythm was obtained, a bolus of adenosine (12 to 36 mg) was administered intravenously. The subsequent response was assessed for each PV (n = 96) using an in situ circular mapping catheter.Results Dormant conduction (i.e., the reappearance of PV potentials during at least one beat) was seen in 1 out of 96 PVs (1%). If reconduction was seen, further endocardial ablation using a 3.5-mm irrigated tip catheter was performed until no more reconduction occurred after repeating the adenosine bolus.Conclusions Adenosine administration after PVI with the use of an epicardial bipolar radiofrequency clamp in the setting of hybrid AF ablation reveals acute reconduction in 1% of the PVs.
- Full Text
- View/download PDF
15. Rate vs. rhythm control and adverse outcomes among European patients with atrial fibrillation
- Author
-
Dimitrios Tahmatzidis, Michał Mazurek, Cécile Laroche, Salvatore Novo, Marco Proietti, Gregory Y.H. Lip, Giuseppe Boriani, Yanish Purmah, and Yanish Purmah, Marco Proietti, Cecile´ Laroche, Michal Mazurek, Dimitrios Tahmatzidis, Giuseppe Boriani, Salvatore Novo, Gregory Y.H. Lip
- Subjects
Male ,Time Factors ,Rate control ,Action Potentials ,Pilot Projects ,030204 cardiovascular system & hematology ,Amiodarone ,Action Potentials/drug effects ,Heart Conduction System/drug effects ,Cardiologists ,0302 clinical medicine ,Heart Rate ,Risk Factors ,Cause of Death ,Atrial Fibrillation ,030212 general & internal medicine ,Registries ,Practice Patterns, Physicians' ,Cause of death ,Aged, 80 and over ,All-cause death ,Atrial fibrillation ,Major adverse events ,Registry ,Rhythm control ,Heart Rate/drug effects ,Middle Aged ,Europe ,Treatment Outcome ,Cohort ,Cardiology ,Healthcare Disparities/trends ,Female ,Cardiology and Cardiovascular Medicine ,Anti-Arrhythmia Agents ,Cardiologists/trends ,medicine.drug ,medicine.medical_specialty ,Anti-Arrhythmia Agents/adverse effects ,Europe/epidemiology ,03 medical and health sciences ,Heart Conduction System ,Physiology (medical) ,Internal medicine ,Heart rate ,medicine ,Atrial Fibrillation/diagnosis ,Humans ,Healthcare Disparities ,Adverse effect ,Aged ,business.industry ,Proportional hazards model ,medicine.disease ,Practice Patterns, Physicians'/trends ,Atrial fibrillation • Rate control • Rhythm control • Major adverse events • All-cause death • Registry ,Propensity score matching ,business - Abstract
Aim The impact of rate and rhythm control strategies on outcomes in patients with atrial fibrillation (AF) remains controversial. Our aims were: to report use of rate and rhythm control strategies in European patients from the EURObservational Research Program AF General Pilot Registry. Secondly, to evaluate outcomes according to assigned strategies. ........................................................................................................................................................... Methods and results Use of pure rate and rhythm control agents was described according to European regions. 1-year follow-up data were reported. Among rate control strategies, beta-blockers were the most commonly used drug. Proportions of patients assigned to rhythm control varied greatly between countries, and amiodarone was the most used rhythm control drug. Of the original 3119 patients, 1036 (33.2%) were assigned to rate control only and 355 (11.4%) to rhythm control only. Patients assigned to a rate control strategy were older (P < 0.0001) and more likely female (P = 0.0266). Patients assigned to a rate control strategy had higher rates for any thrombo-embolic event (P = 0.0245), cardiovascular death (P = 0.0437), and all-cause death (P < 0.0001). Kaplan–Meier analysis showed that rate control strategy was associated with a higher risk for all-cause death (P < 0.001). On Cox regression analysis, rate control strategy was independently associated with all-cause death (P = 0.0256). A propensity matched analysis only found a trend for the association between rate control and all-cause death (P = 0.0664). ........................................................................................................................................................... Conclusion In a European AF patients’ cohort, a pure rate control strategy was associated with a higher risk for adverse events at 1-year follow-up, and partially adjusted analysis suggested that rate control independently increased the risk for all-cause death. A fully adjusted propensity score matched analysis found that this association was no longer statistically significant, suggesting an important role of comorbidities in determining the higher risk for all-cause death.
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.